Drug search by name

Polatuzumab vedotin and Hepatic impairment

Result of checking the interaction of drug Polatuzumab vedotin and disease Hepatic impairment for safety when used together.

Check result:

Polatuzumab vedotin <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

No adjustment in the starting dose of polatuzumab vedotin is required in patients with mild hepatic impairment. The use of polatuzumab vedotin in patients with moderate or severe hepatic impairment should be avoided. Serious cases of hepatotoxicity that were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, have occurred in patients treated with polatuzumab vedotin. This agent has not been studied in patients with moderate or severe hepatic impairment. Patients with moderate or severe hepatic impairment are likely to have increased exposure to the MMAE component, which may increase the risk of adverse reactions. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk of hepatotoxicity. Monitor liver enzymes and bilirubin level as appropriate.

Polatuzumab vedotin

Generic Name: polatuzumab vedotin

Brand Name: Polivy

Synonyms: Polatuzumab Vedotin

What is Polatuzumab vedotin?